Pneumocystis carinii pneumonitis

Infectious Diseases in Clinical Practice

Volumn 6, Issue 6, 1997, Pages 379-384

  Hughes, Walter T ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; BACTERIAL VACCINE; ERYTHROMYCIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; SULFONAMIDE; TRIMETHOPRIM;

ANIMAL MODEL; HUMAN; INFECTIOUS PNEUMONIA; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; SHORT SURVEY;

EID: 0030859659     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199706060-00006     Document Type: Short Survey

References (26)

1. Frenkel JK, Good JT, Shultz JA. Latent pneumocystis infection in rats, relapse, and chemotherapy. Lab Invest 1966;15:1559.
2. Hughes WT, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1974;5:289.
3. Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprimsulfamethoxazole Can Med Assoc J 1975;112:47.
4. Hughes WT, Feldman S, Chaudhary S, Ossi MJ, Cox F, Sanyal SK. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978;92: 285.
5. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419.
6. Hughes WT. Postulates for the evaluation of adverse reactions to drugs. Clin Infect Dis 1995;20:179-82.
7. Hughes WT. Five-year absence of Pneumocystis carinii pneumonitis in a pediatrie oncology center. J Infect Dis 1984;150:305.
8. Hughes WT. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonia. N Engl J Med 1987; 316:1627.
9. Hughes WT, Price RA, Sisko F, et al. Protein-calorie malnutrition: a host determinant for Pneumocystis carinii. Am J Dis Child 1974;128:44.
10. Masur H, Michelis MA, Green JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia. N Engl J Med 1981;305:1431.
11. Hughes WT, Smith BL. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1984;26: 436.
12. Leoung GS, Mills J, Hopewell PC, Hughes W, Wofsy C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:45.
13. Hughes WT, Kennedy W, Dugdale M, et al. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet 1990;336:1066.
14. Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of a hydroxynapthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1990;34:225.
15. Hughes WT, Kennedy W, Shenep JL, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis 1991;163:843.
16. Hughes WT, Leong G, Kramer F, et al. Comparison of atovquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521.
17. Oz H, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus and dexamethasone. J Infect Dis 1997;175:902.
18. Hughes WT, Sillos E, LaFon S, et al. Effects of aerosolized synthetic surfactant, atovaquone and combination of these on murine Pneumocystis carinii pneumonia. J Infect Dis 1997.
19. Oz H, Hughes WT, Rehg J. Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 1997;41:191.
20. Hughes WT, Killmar J. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1996;40:962.
21. Hughes WT, Jacobus DP, Canfield C, Killmar J. AntiPneumocystis carinii activity of PS-15, a new biguanide folate antagonist. Antimicrob Agents Chemother 1993; 37:1417.
22. Hughes WT, Killmar JT. Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. J Acquire Immune Defic Syndr 1991;4:523.
23. Hughes WT. Macrolide-antifol synergism in antiPneumocystis carinii therapeutics. J Protozool 1991;38: 1605.
24. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982; 145:842.
25. Vargas SL, Hughes WT, Wakefield AE, Oz H. Limited persistence and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia. J Infect Dis 1995;172:506.
26. Stagno S, Pifer LL, Hughes WT, Brasfield DM, Tiller RE. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics 1980;66:56.